OSIR up around 28% on a so/so earnings report and MDXG reports and we just sit around. MDXG called out OSIR headwinds on the CC and personally I feel MDXG has the better story .... yet we languish.
Appears the street doesn't plan to pay MDXG any respect OR Management has more work to do.
Looking to short some OSIR today just wish MDXG would react in a better way
Lets see if OSIR's share price has staying power. Short interest increased after their own FDA letter. OSIR doubled on a Grafix multicenter trial. Short covering created a flame (as mentioned smaller float) and the stock settled back down.
One of the attributes I like about investing is that it isn't a zero sum i.e. MDXG's success doesn't depend upon OSIR's failure. OSIR has 1/5 of the float of MDXG. It's even easier to manipulate than MDXG. Quit whining about OSIR stock's success and buy some more MDXG and you may want to buy some OSIR too.
Its insane and makes no sense. Its obvious that MDXG is the better buy and better company. I guess people want a resolution from the FDA on a product that is only 15% of revenue before they jump back in.
Stem-cell drug company Osiris Therapeutics (OSIR:$17.10,00$3.79,0028.47%) is nearly 28% higher in mid-morning trade at $16.99 after said narrowing its Q3 loss to $0.05 per share from $0.09 the year earlier and also coming in ahead of the Capital IQ consensus estimate expecting a $0.10 per share net loss. (DID MDXG LOOSE $$??)
The stock traded as high as $17.23 today but remains significantly below its 52-week high of $27.40.(SURE so it ran from 15 to 27 in a day THATS A LIGITIMATE 52 WEEK HIGH)
Revenues $6.9 million from $2.2 million in the year-ago quarter, exceeding expectations by around $200,000 (MDXG MADE OVER $16 MILLION!)